Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06147063 · ClinicalTrials.gov registry record · Phase 1
A Randomized Trial Evaluating a mRNA-VLP Vaccine's Immunogenicity and Safety for COVID-19
A Phase 1 study, sponsored by AstraZeneca.
- Completed
- Registry status
- Phase 1
- Development phase
- 243
- Enrollment target
NCT06147063: Completed Phase 1 study, sponsored by AstraZeneca.
NCT06147063 is a Phase 1 study that has completed, run by AstraZeneca. The registered enrollment target is 243 participants, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (305% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06147063, a Phase 1 study, has completed, sponsored by AstraZeneca.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 243 participants
- Enrollment target
Study Summary
The purpose of this study is to characterize the safety and immunogenicity of AZD9838 and AZD6563 when administered as a single dose vaccination against SARS-CoV-2 in adults.
Primary Outcome
Immediate unsolicited AEs were defined as having an onset within 30 minutes post vaccination.
Interventions
- BIOLOGICAL AZD9838
- BIOLOGICAL Licensed mRNA vaccine
- BIOLOGICAL AZD6563
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 243 participants |
| Start Date | 2023-11-27 |
| Est. Completion | 2025-03-27 |
| Phase | Phase 1 |
What the finished NCT06147063 record still lists
NCT06147063 is an interventional study that assigns participants to a tested intervention. The registered 243 participants enrollment target is mid-sized for trials with a published cap, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (305% higher).
The record links to 0 conditions, and to 3 interventions - of which AZD9838 is the first listed.
NCT06147063 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT06147063 about?
NCT06147063 is a clinical study titled "A Randomized Trial Evaluating a mRNA-VLP Vaccine's Immunogenicity and Safety for COVID-19". The purpose of this study is to characterize the safety and immunogenicity of AZD9838 and AZD6563 when administered as a single dose vaccination against SARS-CoV-2 in adults.
What is the current status of trial NCT06147063?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 243 participants. The study started on 2023-11-27. Estimated completion is 2025-03-27.
What interventions are being tested in trial NCT06147063?
The interventions under investigation include: AZD9838 (BIOLOGICAL), Licensed mRNA vaccine (BIOLOGICAL), AZD6563 (BIOLOGICAL).
Who is sponsoring clinical trial NCT06147063?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT06147063's enrollment target sits among peer trials
243 193rd of 2000 higher than 1,807 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06253871 · 243 participants · Phase 1
A Phase 1/1b Study of IAM1363 in HER2 Cancers
- NCT06289491 · 243 participants · NA
A Trial of Hydrus Microstent Versus Goniotomy
- NCT06536296 · 243 participants · NA
The Impact of Music Medicine on Preterm Brain Development and Behavior
- NCT06907615 · 243 participants · Phase 2
A Phase II Clinical Study to Evaluate HLX43 in Subjects With Advanced Non-small Cell Lung Cancer (NSCLC)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI